{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T08:26:32Z","timestamp":1790065592852,"version":"4.0.1"},"reference-count":41,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue des Maladies Respiratoires"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.rmr.2013.12.001","type":"journal-article","created":{"date-parts":[[2014,1,4]],"date-time":"2014-01-04T08:47:06Z","timestamp":1388825226000},"page":"336-346","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Mucoviscidose et traitements inhal\u00e9s\u00a0: quoi de neuf en 2013\u00a0?"],"prefix":"10.1016","volume":"31","author":[{"given":"J.-C.","family":"Dubus","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bassinet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Chedevergne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Delaisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Desmazes-Dufeu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Reychler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Vecellio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.rmr.2013.12.001_bib0005","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1089\/jamp.2010.0855","article-title":"Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere\u2122 technology","volume":"24","author":"Geller","year":"2011","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.rmr.2013.12.001_bib0010","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1089\/jam.2006.19.456","article-title":"Effect of dry powder inhaler resistance on the the inspiratory flows and volumes of patients with cystic fibrosis of six years and older","volume":"19","author":"Tiddens","year":"2006","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0015","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1164\/ajrccm.156.5.9604093","article-title":"RhDNase I aerosol deposition and related factors in cystic fibrosis","volume":"156","author":"Diot","year":"1997","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0020","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1365-2281.1999.00170.x","article-title":"The effect of breathing frequency on deposition of drug aerosol using an inhalation-synchronized dosimeter in healthy adults","volume":"19","author":"Hakkinen","year":"1999","journal-title":"Clin Physiol"},{"key":"10.1016\/j.rmr.2013.12.001_bib0025","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1089\/jam.2005.18.45","article-title":"Optimum peripheral drug deposition in patients with cystic fibrosis","volume":"18","author":"Brand","year":"2005","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0030","doi-asserted-by":"crossref","first-page":"S78","DOI":"10.1089\/jam.2007.0572","article-title":"Facemasks and aerosol delivery in vivo","volume":"20","author":"Erzinger","year":"2007","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0035","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1136\/thoraxjnl-2013-203309","article-title":"A randomised, double-blind, placebo-controlled phase IIB clinical trial of repeated application of gene therapy in patients with cystic fibrosis","volume":"68","author":"Alton","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2013.12.001_bib0040","doi-asserted-by":"crossref","first-page":"S29","DOI":"10.1089\/jamp.2009.0768","article-title":"Evaluation of the target inhalation mode (TIM) breathing maneuver in simulated nebulizer therapy in patients with cystic fibrosis","volume":"23","author":"Denyer","year":"2010","journal-title":"J Aerosol Med Pulm Drug Deliv"},{"key":"10.1016\/j.rmr.2013.12.001_bib0045","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1183\/09031936.00118408","article-title":"Lung deposition of inhaled alpha1-proteinase inhibitor in cystic fibrosis and alpha1-antitrypsin deficiency","volume":"34","author":"Brand","year":"2009","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2013.12.001_bib0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1002\/(SICI)1520-6017(200006)89:6<724::AID-JPS3>3.0.CO;2-B","article-title":"Total deposition of therapeutic particles during spontaneous and controlled inhalations","volume":"89","author":"Brand","year":"2000","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.rmr.2013.12.001_bib0055","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1183\/09031936.03.00096802","article-title":"Peripheral deposition of alpha1-protease inhibitor using commercial inhalation devices","volume":"22","author":"Brand","year":"2003","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2013.12.001_bib0060","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1089\/jam.2005.18.386","article-title":"Lung deposition after electronically breath-controlled inhalation and manually triggered conventional inhalation in cystic fibrosis patients","volume":"18","author":"Kohler","year":"2005","journal-title":"J Aerosol Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0065","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1055\/s-2003-44262","article-title":"Controlled inhalation of beta2-sympaticomimetics after bronchial provocation","volume":"57","author":"Meyer","year":"2003","journal-title":"Pneumologie"},{"key":"10.1016\/j.rmr.2013.12.001_bib0070","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1183\/09031936.00006211","article-title":"Improved treatment response to dornase alfa in cystic fibrosis patients using controlled inhalation","volume":"38","author":"Bakker","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2013.12.001_bib0075","first-page":"CD001506","article-title":"Nebulised hypertonic saline for cystic fibrosis","volume":"2","author":"Wark","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2013.12.001_bib0080","doi-asserted-by":"crossref","first-page":"1517","DOI":"10.1164\/rccm.201101-0072OC","article-title":"Nebulized hypertonic saline decreases IL-8\u00a0in sputum of patients with cystic fibrosis","volume":"183","author":"Reeves","year":"2011","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0085","first-page":"119","article-title":"Hypertonic saline increases lung epithelial lining fluid glutathione and thiocyanate: two protectice CFTR-dependent thiols against oxidative injury","volume":"11","author":"Gould","year":"2010","journal-title":"Respir Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0090","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.jcf.2007.11.009","article-title":"Inhibitory effects of hypertonic saline on P.\u00a0aeruginosa motility","volume":"7","author":"Havasi","year":"2008","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.rmr.2013.12.001_bib0095","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa043900","article-title":"A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis","volume":"354","author":"Elkins","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0100","doi-asserted-by":"crossref","first-page":"e000019","DOI":"10.1136\/bmjopen-2010-000019","article-title":"Stratified assessment of the role of inhaled hypertonic saline in reducing cystic fibrosis pulmonary exacerbations: a retrospective analysis","volume":"1","author":"Dmello","year":"2011","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmr.2013.12.001_bib0105","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1001\/jama.2012.5214","article-title":"Inhaled hypertonic saline in infants and children younger than 6\u00a0years with cystic fibrosis: the ISIS randomized controlled trial","volume":"307","author":"Rosenfeld","year":"2012","journal-title":"JAMA"},{"key":"10.1016\/j.rmr.2013.12.001_bib0110","doi-asserted-by":"crossref","first-page":"e000407","DOI":"10.1136\/bmjopen-2011-000407","article-title":"Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study","volume":"2","author":"Pezzulo","year":"2012","journal-title":"BMJ Open"},{"key":"10.1016\/j.rmr.2013.12.001_bib0115","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1177\/1753465812458984","article-title":"Nebulized hypertonic saline containing hyaluronic acid improves tolerability in patients with cystic fibrosis and lung disease compared with nebulized hypertonic saline alone: a prospective, randomized, double-blind, controlled study","volume":"6","author":"Furnari","year":"2012","journal-title":"Ther Adv Respir Dis"},{"key":"10.1016\/j.rmr.2013.12.001_bib0120","first-page":"292","article-title":"Tolerability of hypertonic saline when delivered rapidly via the e-Flow rapid nebulizer in subjects with cystic fibrosis [Abstract]","volume":"41","author":"Elkins","year":"2006","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2013.12.001_bib0125","first-page":"CD008816","article-title":"Timinig of hypertonic saline inhalation for cystic fibrosis","volume":"2","author":"Elkins","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.rmr.2013.12.001_bib0130","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1136\/adc.2008.141226","article-title":"Question 2: should hypertonic saline be used in patients with cystic fibrosis who respond unsatisfactorily to recombinant deoxyribonuclease?","volume":"95","author":"Baduredeen","year":"2010","journal-title":"Arch Dis Child"},{"key":"10.1016\/j.rmr.2013.12.001_bib0135","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1002\/ppul.10442","article-title":"Prediciting response to rhDNase and hypertonic saline in children with cystic fibrosis","volume":"37","author":"Suri","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2013.12.001_bib0140","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1164\/ajrccm.159.6.9809074","article-title":"Inhalation of dry powder mannitol improves clearance of mucus in patients with bronchiectasis","volume":"159","author":"Daviskas","year":"1999","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0145","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1378\/chest.09-2017","article-title":"Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis","volume":"137","author":"Daviskas","year":"2010","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2013.12.001_bib0150","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcf.2010.08.020","article-title":"Inhaled mannitol in patients with cystic fibrosis: a randomised open-label dose response trial","volume":"10","author":"Teper","year":"2011","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.rmr.2013.12.001_bib0155","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1183\/09031936.00187510","article-title":"Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study","volume":"38","author":"Bilton","year":"2011","journal-title":"Eur Respir J"},{"key":"10.1016\/j.rmr.2013.12.001_bib0160","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1164\/rccm.201109-1666OC","article-title":"Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study","volume":"185","author":"Aitken","year":"2012","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0165","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1378\/chest.08-1421","article-title":"Efficacy and safety of inhaled aztreonam lysine for airway Pseudomonas in cystic fibrosis","volume":"135","author":"Retsch-Bogart","year":"2009","journal-title":"Chest"},{"key":"10.1016\/j.rmr.2013.12.001_bib0170","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1164\/rccm.200712-1804OC","article-title":"Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis","volume":"178","author":"McCoy","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.rmr.2013.12.001_bib0175","doi-asserted-by":"crossref","first-page":"1121","DOI":"10.1002\/ppul.21301","article-title":"An 18-month study, AIR-CF3, of the safety and improvement in pulmonary function and respiratory symptoms with repeated courses of aztreonam for inhalation solution in patients with cystic fibrosis and airway Pseudomonas aeruginosa","volume":"45","author":"Oermann","year":"2010","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2013.12.001_bib0180","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1517\/14656566.2010.482102","article-title":"Optimal airway antimicrobial therapy for cystic fibrosis: the role of inhaled aztreonam lysine","volume":"11","author":"Elborn","year":"2010","journal-title":"Expert Opin Pharmacother"},{"key":"10.1016\/j.rmr.2013.12.001_bib0185","article-title":"Inhaled aztreonam lysine vs. inhaled tobramycin in cystic fibrosis: a comparative efficacy trial","author":"Assael","year":"2012","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.rmr.2013.12.001_bib0190","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1136\/thoraxjnl-2012-202059","article-title":"Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study","volume":"68","author":"Schuster","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.rmr.2013.12.001_bib0195","first-page":"284","article-title":"Young cystic fibrosis patients can effectively use a novel high-payload capsule-based dry powder inhaler with tobramycin powder for inhalation (TPI)","volume":"38","author":"Standaert","year":"2004","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2013.12.001_bib0200","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1002\/ppul.21356","article-title":"Tobramycin Inhalation powder for P.\u00a0aeruginosa infection in cystic fibrosis: The EVOLVE trial","volume":"46","author":"Konstan","year":"2011","journal-title":"Pediatr Pulmonol"},{"key":"10.1016\/j.rmr.2013.12.001_bib0205","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.jcf.2010.10.003","article-title":"Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial","volume":"10","author":"Konstan","year":"2011","journal-title":"J Cyst Fibros"}],"container-title":["Revue des Maladies Respiratoires"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842513010073?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0761842513010073?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T21:22:52Z","timestamp":1565040172000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0761842513010073"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":41,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S0761842513010073"],"URL":"https:\/\/doi.org\/10.1016\/j.rmr.2013.12.001","relation":{},"ISSN":["0761-8425"],"issn-type":[{"value":"0761-8425","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mucoviscidose et traitements inhal\u00e9s\u00a0: quoi de neuf en 2013\u00a0?","name":"articletitle","label":"Article Title"},{"value":"Revue des Maladies Respiratoires","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rmr.2013.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 SPLF. Published by Elsevier Masson SAS All rights reserved.","name":"copyright","label":"Copyright"}]}}